Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Frog,It is not that relevant information is avoided like the plague on either board it is simply that most of the posters here and On the RB are avoided like the Plague. Most if not all of the good posters simply dont want to share anything with the rest of you. I have found many good things BUT you and the others here are not worth it.
DNAPrint Launches EURO-DNA(TM) 1.0
Friday August 27, 4:40 pm ET
SARASOTA, Fla., Aug. 27 /PRNewswire-FirstCall/ -- DNAPrint genomics (OTC Bulletin Board: DNAP - News; the "Company") announces today that it has launched EURO-DNA(TM) 1.0, the world's first genetic test for determining intracontinental subpopulation (i.e. "ethnic") admixture.
EURO-DNA(TM) 1.0 provides customers their percentages of Northern European, Southeast European (Mediterranean), Middle Eastern and South Asian ancestry and is appropriate for most customers who obtained at least 50% European admixture with the ANCESTRYbyDNA(TM) 2.5 test. The new test, which works in the same manner as the company's ANCESTRYbyDNA(TM) 2.5 test, is powered by 309 proprietary Ancestry Informative Markers (AIMs) distributed across all 23 human chromosomes. The AIMs were identified from a screen of approximately 12,000 candidate AIMs obtained from DNA chips and public genome database resources. Research conducted by DNAPrint(TM) suggests that for the average customer, the test is accurate to within about 7 percentage points.
Since the test looks back farther in time than most genealogical records extend, EURO-DNA(TM) 1.0 provides a different glimpse of a person's heritage than most genealogists are accustomed to, and thus might be better described as a personal anthropology test rather than a genealogy test. In fact, since the test reports anthropological identity, not necessarily geopolitical identity, some customers may be surprised by their results. For example, a blond haired/blue eyed Italian whose ancestors migrated from Scandinavia 1,000 years ago might describe him/herself as Italian or Mediterranean, but share more in common genetically with Scandinavians; such an individual would demonstrate relatively polarized Northern European ancestry with the new EURO-DNA(TM) 1.0. These results are important to genealogists tracing lineage and can also help reconstruct human migration patterns on a recent evolutionary timescale.
Until today, the only genetic tests capable of tracing ethnic ancestry were Y-chromosome and mtDNA tests. Y-chromosome and mitochondrial DNA (mtDNA) tests only look at a specific portion of a person's DNA heritage - the Y- chromosome, which is inherited paternally and the mtDNA, which is inherited maternally. Because Y and mtDNA tests each look at only 1 of the 23 chromosomes, they ignore contribution from most of the individuals in a given family tree and for this reason, Y and mtDNA tests are not useful for the analysis of admixture within individuals. EURO-DNA(TM) 1.0 is the first test ever developed and commercialized capable of telling the "whole" ethnic story from each persons DNA "book".
Since EURO-DNA(TM) 1.0 is the first test for determining "ethnic" admixture within individuals; there are no other tests against which to compare it directly. In contrast, Y-chromosome and mtDNA tests are quite useful for analysis of populations, since their defect is overcome by averaging over large numbers of individuals. Previous work on European populations using Y-chromosome and mtDNA reveal northwest to southeast trends and clines across Europe, the Middle East and South Asia. Using EURO-DNA(TM) 1.0, DNAPrint(TM) scientists have found similar trends. Although they only report on a small fraction of your genetic make-up, Y and mtDNA tests are complimentary to EURO-DNA(TM) 1.0, and maybe used in conjunction with EURO- DNA(TM) 1.0 to produce the most comprehensive picture of ancestry from your DNA. For example, if EURO-DNA(TM) 1.0 reports Middle Eastern admixture for a person, it cannot say which ancestors contributed it, but a Y and mtDNA test could potentially identify whether the mother or father (or both) were the source.
DNAPrint(TM) will employ the test as a consumer genomics, forensics and as a tool for the development of more specific, better tolerated and more effective drugs. Customers can learn more about the test at www.ancestrybydna. The new test will cost $199 for former DNAPrint customers who have already taken or ANCESTRYbyDNA(TM) 2.5 test. New customers that are interested in the new service test can purchase the combined test for $399 which will include the ANCESTRYbyDNA(TM) 2.5 test and the new EURO-DNA(TM) 1.0 test. The combined new test will be measuring 309 unique ancestry informative markers that span the entire human genome. Customers that do not meet the test's criteria or cut off for EURO-DNA(TM) 1.0 will only be billed the ANCESTRYbyDNA(TM) 2.5 test price of $219.00.
About DNAPrint genomics, Inc.
DNAPrint genomics Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company introduced Ancestrybydna in the consumer market and DNA Witness in the forensic market in 2003. DNAPrint is developing products in the pharmacogenomic market and has a disease gene discovery program. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit www.dnaprint.com.
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Media and Press Contacts
Richard Gabriel
DNAPrint Genomics, Inc.
CEO/President
(941) 366-3400
ming - while you are removing posts, please be sure and remove post #16765 as this was a "personal attack" against me. Thank you.
There are many differences between the sage and the discontent. In the beginning they appear the same as time passes their differences become very apparent.Time will tell.Take RB for an example - The discontent has remained so for the duration of time there. The sage has Moved on.{in more ways than one}Time will tell. History checks are very telling.
altarboy4,Thankyou and God Bless.
To me pr's and outstanding Dont matter.What matters is,is Dnap bringing in enough revenue to stabilise.Is money coming in, is a lot of money coming in.
Now is a Good time to Note the Outstanding share count. Outstanding Shares = 733,742,119 as of 8-2-04
Dnap's Outstanding Shares = 733,742,119 as of 8-2-04
DorseyE, only up to a point.The small fish and their gloom and doom do not work when the big boy step in to play. Believe me when there is real money to be made they make the difference and the gloom and doom cloud gets blow away.
trustedbyMany, I agree in part the outstanding is a real problem But a FDA approval on one of our products would still blow the outstanding away thats if it doesent get much bigger from here. Now I see the Forensics products as a stabiliser to the outstanding shares till we get FDA approval thats not far off. Think of it as a "stabiliser" and when hair color come out the outstanding will stop growing it will stop in its track.IMO the pps may not grow much But the incomming of events and moneys to dnap from here on in will effect in a big way the Outstanding keeping it stable till the big FDA come along
twelks,yes i do agree. I think in order to get the kind of volume we need Dnap will have to come out with another feature or FDA approval on something.Hair color was to be out this year.Tony indicated it would be out near the end of the year i hope so.
goliath65 Thanks for your support i do believe i'm back on track
Trustedbymany, its not the outstanding shares that matter its the volume.There simply is no volume here,80 to over 100 million is what is needed till then we get zip
retro,you are right and i agree thanks .Perhaps i should say that i'm not going to put into searching and finding like before. I'm backing off i will continue to read the board and post once in a while.I will respond to other posters but the researching is out and gone.As you say "the comp. fell out of favor with me" applys to me as well.
twelks,take a look at this news release that just came out.Take a good look at how bad Dnap wants police dept to use Dnapwitness tm.This alone tell me if they could put out 3.0 and or eye & hair color they would.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
{We will be contacting as many agencies, police and investigators as possible
over the next two to three weeks, right up to the last minute, to try and encourage investigators and grant submitters to include DNAWitness(TM) as a part of their grant proposals," said Zach Gaskin,}
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
But in fact they cant and by now Mid Aug.2004 they should have been able to based on what we have been told by Tony in the past.Based on post 16745 and this news release i think we are not going to see much of anything till spring of 2005 maybe. God Bless
I will not wasting anymore of my time here or with this comp. see ya in 2005 maybe. Good luck and God Bless
NOTHING FOR 2004 - see post by Grateful -
http://www.goldcoastforensics.com/modules.php?name=News&new_topic=1
The Gold Coast Forensic Association will hold it's Bimonthly Training Meeting on August 17, 2004 at the West Palm Beach Police Department 600 Banyan Blvd. West Palm Beach,Florida @ 7:00 PM in the Community Room Topic is Introduction to Underwater Crime Scenes with Sgt. Todd Peney of the Ft. Lauderdale Police Department. Also during the PBSO/DNA Training PBSO asked for volunteers for DNAPrint Genomics. The Laboratory personnel will be here to take samples and fill out the paper work for this free testing, be ready to participate. Here is brief description of the type of analysis that will be conducted and the procedure for collecting the DNA samples: DNAPrint Genomics (http://www.dnaprint.com/cp.html) is a private company that is based in Sarasota. They routinely conduct DNA analysis for "BioGeographical Ancestry" or "BGA" on casework evidence from law enforcement agencies throughout the United States. (see powerpoint slide attached). They are currently developing a DNA test to determine hair and eye color from an individual's DNA. In order to developed and validate the hair and eye color test, DNAPrint is seeking volunteers to provide 2 cheek swabs. As a thank you for participating in the study, DNAPrint Genomics will conduct Biogeographical Ancestry analysis on the DNA samples and send the volunteers their DNA ancestry. All volunteers will receive a CD that contains information about how genetic information is transferred or inherited, what the 4 different Bio Geographical Ancestries are (European, Sub-Saharan African, East- Asian, and Native American), their DNA sequence that was used to determine Ancestry, and a description of how the analysis is performed and interpreted. I volunteered to participate and have received my CD. It is very informative and quite interesting with a lot of information packed into that CD. The actual process of collecting the DNA will only take a few minutes for each volunteer. They are provided documentation that describes the test, explains how your samples will be used, asks for some personal information that the volunteer will need to fill out, and includes a privacy statement as well. Filling out the form is actually the longest part of the process. The information that is requested is what is your natural hair and eye color? Describe how you would classify your self (Caucasian, Phillipino, Bahamian, etc). How would you classify your mother, father, paternal and maternal grandparents? What is your country of origin? What is the country of origin for your mother, father, paternal and maternal grandparents? They also ask you to provide a mailing address of where you would like your CD sent. The next step includes a digital photograph of the volunteers' face, hair, and eyes. The volunteer then swabs the inside of their mouth and places them in a sealed labeled envelope. The swabs, paper work, and photos are then sent to DNAPrint Genomics for testing. In about 6 weeks the volunteers will receive their results. Our intern, Clay, will be responsible for collection of all necessary samples and paperwork. Cecelia Crouse and I will be attending the meeting to help with the collection process. We are especially interested in volunteers who have unusual eye color or two different eye colors. In all it is a pretty straight forward and simple procedure. DNA Print Genomics has already conducted this test on nearly 1000 individuals. PBSO has committed to providing DNA samples from 400 individuals. If you can think of any other collection site venues for obtaining these samples, especially within the next month or so, we would be most appreciative. Thank you in advance for all your help. <> King C. Brown Crime Scene Supervisor West Palm Beach Police Department 600 Banyan Blvd. West Palm Beach, Florida 33401
I hate to say it but it looks like stockholder might have been right. We will see the pps go down to a penny and most likely below. Nothing much for 2004,Shot dead in the water,see ya in 2005.
Grateful this is not good.They did something like this last year.BUT IF they have to do something like this again,NOW,then i have to say we wont see eye and hair comming out till next year 2005, if at all,no sir its not good at all,NOTHING FOR 2004. I am not happy about this and i'm at the point now after seeing this that it might all be a bunch of BULL**** and Dnap has been lieing all along.Untill i see something come out on this Dnap will no longer get my support.
New York University
DNAprint genomics is engaged in a partnership with the New York University School of Medicine to develop pharmacogenomic classifiers for organ transplant patients.
The goal of the project is to identify pharmacogenomic classifiers that could be used to match renal transplantation patients with the optimal immunosuppressant for their genetic architecture. The project is expected to take about one year to complete, and the results are expected to extend to patients for a wide range of transplantation procedures.
About NYU's Transplant Program:
The Mary Lea Johnson Richards Organ Transplantation Center is one of the busiest and most successful transplant programs in the United States. The program offers transplantation of the liver, kidney and pancreas and performs about 150 transplants annually. Over 500 liver and 200 kidney transplants have been done since program inception and the programs graft and patient survival rates are consistently among the best in the country.
bag8ger,I dont think there much of a concern. Also if they did abandoned their bus. plan on statnome it would have beed on their legal counsel advise and that fairs very well for Dnap.Just another confirmation were ahead Hands down.
Wisdom of the day - A barking dog is often more useful than a sleeping lion.
I think Genaissance is far behind Dnap because of the way the CEO talks about their progress. Just this past march 2003 they were talking about gene association with ony 3 statnomes {Atorvastatin ; Provastatin ; Simvastatin} over a 16 week trial {thats nothing} by project name Strength Study.Where Dnap From the first Newsletter: Aug 17,2001
OTHER TESTS - We have finished both the genotyping and the computational screening for Lipitor and Zocor, and we have finished the genotyping but not the computational screening for about 15 other drugs we have good sample sizes for. As we complete these projects, we will disclose the results within a formal, peer-reviewed setting such as a professional meeting or in the scientific literature. AND At present our scientists have completed the screen of the xenobiotic genome for the Statnome project and are validating the performance of the resulting classifier. It is clear that Dnap is far ahead of the pack.
bag8ger,read this and tell me how do you know about the position of Genaissance can you point me to the post that indicates it. Thanks again. ---- http://www.bio-itworld.com/news/050702_report258.html?action=print
Targeted Therapy Makes a Stand
By Malorye Branca
Bio-IT World
BOSTON (05/07/02)—A series of study results and a new stance by the Food and Drug Administration may provide badly needed fuel for pharmacogenomics. The study of why individuals respond differently to drugs — pharmacogenomics — is one of the most potentially exciting applications of the Human Genome Project. In the not-too-distant future, doctors will be able to use patients' unique genetic profiles to guide treatment decisions, and medicines will be tailored to genetic makeup.
But despite widespread anticipation of the promise of pharmacogenomics, surprisingly few findings to date have supported this view. "There was a big wave of investment in this field awhile ago, and people found it was harder to get results than they thought," says Dennis Henner of MPM Capital.
As a result, the field is losing steam. Some of the smaller pioneering pharmacogenomics companies are anxious to reverse that trend.
Researchers at Genaissance Pharmaceuticals, based in New Haven, Conn., recently reported "statistically significant" relationships between genetic markers and patient responses to cholesterol-lowering drugs, called statins. If confirmed, these relationships could lead to pharmacogenetic tests to determine which drug will work best in a particular patient.
"Number one, it [the study] validates what we are doing, and that we can identify these variations that predict response to therapeutic agents," says Dr. Carol Reed, executive director of medical affairs at Genaissance. "Secondly, the associations are significant."
"Genaissance does not sell any of these drugs, and they are the most successful category of drugs in pharmaceutical history," says Peter Tollman of the Boston Consulting Group. "If these associations are significant enough, this could create a very interesting dynamic. We will see a whole new set of competitors going after the Big Pharma drugs, and a need to respond by Big Pharma."
These results come from an initial analysis of the company's STRENGTH I (Statin Response Examined by Genetic HAP Markers) study, which involved simvastatin (Merck & Co.'s Zocor); atorvastatin (Pfizer's Lipitor); and pravastatin (Bristol-Myers Squibb's Pravachol). The study originally also involved cerivastatin (Bayer's Baycol), but Genaissance discontinued the Baycol arm of the study when that drug was voluntarily withdrawn from the market last summer after some patients taking it developed potentially fatal side effects. A second study, STRENGTH II, is also nearing completion. It includes the three drugs left in STRENGTH I, as well as lovastatin (Merck's Mevacor).
The statins represent a huge market. According to IMS Health, Lipitor and Zocor were the second and third top-selling drugs in the world in 2000. IMS recorded almost $16 billion in worldwide sales for cholesterol- and triglyceride-lowering drugs that year.
Statin therapy aims to reduce blood levels of LDL (bad) cholesterol and to improve the ratio of HDL (good) cholesterol to bad. Genaissance has been looking for links between genetic markers and changes in the levels of cholesterol and triglycerides in patients taking these drugs.
Genaissance uses sequencing to find genetic variations called single nucleotide polymorphisms (SNPs) in human DNA. This requires many samples, from the right mix of people, to get a good representation of a target population. The company applies proprietary algorithms to find sets of SNPs, called haplotypes, which are inherited. The goal is to find haplotypes that are "red flags" of disease susceptibility or drug response.
Studying haplotypes, rather than individual SNPs, reduces the number of patients needed for these types of trials because combinations of markers provide a stronger signature than single markers. Genaissance has compiled a database of more than 5,000 such haplotypes, which they call HAP markers. The company has also identified 100 genes that may be linked to patient response to statins.
If further testing confirms the study results, it could lead to products for Genaissance and to better treatment for patients. Tollman, however, advises caution. "The study is small and has other limitations," he says.
In STRENGTH I about 150 patients received each particular type of statin. Overall, more than 500 patients were enrolled. Analysts and researchers are waiting for more details before deciding the study's importance.
Signs of Hope for Pharmacogenomics?
New studies suggest genetic tests can predict who will do best on therapy using these major drugs. For example, DNAPrint Genomics' study indicated which patients would respond best to Taxol.
Drug Studied/Indication
Source of study
Reference/Date
Estrogen replacement therapy/High cholesterol (cardiovascular disease)
Wake Forest University School of Medicine
New England Journal of Medicine, March 28, 2002
Taxol/Ovarian cancer
DNAPrint Genomics and the University of Miami (Fla.)
Presented at the Society of Gynecological Oncology, March 19, 2002
Statins (Lipitor, Pravachol, Zocor)/High cholesterol
Genaissance Pharmaceuticals
Press release at www.genaissance.com, March 26, 2002
Ziagen/AIDS
Royal Perth Hospital and Murdoch University, Perth, Australia
The Lancet, March 2, 2002
GlaxoSmithKline The Lancet, March 30, 2002
"We did the press release to let the clinical world and investor world know that the study is complete, and that we are analyzing the data, and that there is interesting data there," says Reed, adding that the company plans to publish and present findings from the study throughout the year. (The first presentation was planned for late April, after this issue went to press.) "The study was big enough for us to derive statistically relevant correlations. We expect to derive commercial value from these associations."
FDA's Positive Position
Perhaps the biggest hurdle to pharmacogenomics has been the perception that the FDA would resist the introduction of these tests. "The FDA never actually said this, but many people believed that the FDA would never allow these types of tests to be approved," says Allen Roses, senior vice president of genetic research at GlaxoSmithKline (GSK), which is a leading player in this field.
But a timely new announcement from the FDA may clear up that perception. "Now the FDA has come out and said, quite dramatically, 'Yes, we will look at this,'" says Roses, referring to a recent article in The Pharmacogenomics Journal by Lawrence J. Lesko and Janet Woodcock, two FDA officials. Lesko and Woodcock reported that the FDA has received more than 15 recent applications involving pharmacogenomic tests, and that it is taking steps "to assure that, as a regulatory agency, FDA is prepared to deal with the future influx of [pharmacogenomic data]."
Genaissance's Reed agrees with Roses about the impact of the article. "This could really change things," she says. With the FDA's go-ahead, more companies may enter the field, and smaller companies may have less difficulty convincing partners and investors that they can succeed.
With the exception of GSK, leading pharmaceutical companies have been slow in carrying out or funding pharmacogenetic studies of drugs that are already on the market. Last year Jurgen Drews, president of Genaissance and a former president of global research at Roche Pharmaceuticals, was quoted in The Wall Street Journal as saying that pharmaceutical companies were afraid of discovering "the limitations of their drugs."
If pharmacogenetic tests can cause doctors to change prescribing practices, it could erode some drugs' market shares. But it is hard to tell what is keeping Big Pharma away. "I don't think big companies are trying to delay the development of these tests," says Henner. "The technology just hasn't yet moved to a point where they see the value of it."
Large pharmas and genomics firms have shown greater interest in applying pharmacogenomics to early-stage drug candidates. By finding out early on that a potential drug has serious side effects in some patients, or by identifying therapies that only work well in a subgroup of people, companies can save on drug development costs. Later, companies may market the therapies and the tests used with them together.
In the meantime, investors may have already grown weary of waiting for results. "Before pharmacogenomics can come into widespread use, these companies will have to show that the data they provide will make a difference to patients, and that doctors can actually use it," say Henner. "Meanwhile, there are a lot of other biotech products that are going to happen much sooner, so that's where the money is going."
Tide Turning?
During the last few months, there has been a small, but noticeable trickle of results from pharmacogenetic studies (see table). The next step must be to turn these results into actual products.
Early pharmacogenetic tests "looked at extreme responses," says Tony Frudakis, CEO of pharmacogenomics startup DNAPrint Genomics of Sarasota, Fla. "They have looked at too few genes and too few sites in those genes to be useful for more than a very few patients." To become clinically accepted, tests need to work across a wide range of patients. "We are close to this, and Genaissance is close," he says.
DNAPrint recently announced finding genetic markers linked to patient response to paclitaxel (Bristol-Myers Squibb's Taxol). The company uses an approach similar to that of Genaissance. It hopes to develop a test that will flag those patients who will not have a good response to the drug in order to redirect them to other therapies.
"The answer now relies on how good your informatics are," says Frudakis. "We're doing complex genetics now, and there are no algorithms out there to do this. You have to develop them yourself."
Even with powerful algorithms, clinical trials cost money. "The big companies should be funding these kinds of studies and making better tools out of these drugs," says Frudakis. "But addressing the current drugs falls on the shoulders of companies like us and Genaissance." Still, Frudakis remains optimistic. "We are writing an NIH grant right now," he says. "If we can get funding, we might have a product on the market in two to three years."
However, GSK's Roses is skeptical about whether smaller companies can pay for effective pharmacogenomic studies. "We have made a sizable investment in informatics for this, and we are already doing many different clinical studies all the time," says Roses.
GSK, he says, embraced the field early. "We could see that what is good for the patient is good for us," Roses says. Other large pharmaceutical companies may have been slower to climb onboard, he says, because "big pharmas are not mainly R&D organizations; they are sales and marketing organizations, so the people at the top may not fully understand the potential here."
Reason - try Dr. Paul McKeigue
Why is GLAXOSMITHKLINE in with UM/Sylvester can you guess
Protocol #: 2003061
Title: AN OPEN-LABEL,MULTICENTER,SINGLE ARM PHASE II STUDY OF ORAL GW572016 AS SINGLE AGENT THERAPY IN SUBJECTS WITH ADVANCED OR METASTATIC BREAST CANCER WHO HAVE PROGRESSED WHILE RECEIVING HERCEPTIN-CONTAINING REGIMENS
Phase: II
Sponsor: GLAXOSMITHKLINE GROUP
Sponsor Group: INDUSTRIAL
Principal Investigator: TANG, SHOU-CHING
One foot note - Monica is not much different than Richard,you get nothing from either.
Richard and Tony are completely different just like a car engine is completely different from the alternator but one cant run without the other.Tony gave us some info. Richard will not.END OF Story
Wisdom of the day - God gives every bird its food, but he does not throw it into the nest
Ovanome Executive Summary: Part 1
EXECUTIVE SUMMARY OF OVANOME
DNAP has achieved a milestone in the field of chemotherapy. On March 19, 2002, DNAPrint and University of Miami doctors presented the successful results of an ongoing pharmacogenomics study to the Society of Gynecological Oncology. The team identified a set of variant human genes that may be used to predict therapeutic outcomes for Paclitaxel (Taxol), one of the most commonly used chemotherapeutic agents for cancer. The product of this discovery is OVANOME, and it?s introduction is expected to boost the first-line paclitaxel response rate in chemo-niave ovarian cancer patients.
OVANOME is a pharmacogenomics product known as a classifier or chemo-predictive test. OVANOME will be used to predict the likelihood of response of ovarian cancer patients to therapy with Paclitaxel (Taxol). Patients that fail the first round of treatment have substantially lower survival statistics. By matching ovarian cancer patients with the drug most appropriate for their genetic constitution, OVANOME has the potential to save lives through pharmacogenomics testing. OVANOME demonstrated excellent sensitivity, specificity and predictive value in preliminary tests.
DNAPrint scientists used an innovative heuristic method with geometrical projection to identify and model proprietary ?eigengenotypes?' or population based vectors of genome information, that serve as features for variable Paclitaxel response. The team found that certain Paclitaxel response ?eigengenotypes? were strongly predictive for first-line chemotherapy response in Ovarian Cancer patients. Data was shown that suggests that by screening patient genomes for these ?eigengenotypes? prior to the commencement of chemotherapy, most non-responders could be flagged and re-directed towards altered doses and/or alternative chemotherapy more appropriate for their genetic constitution.
. The clinical trial for OVANOME will be finished in early 2004 An application for approval to market, if required, will be submitted to the FDA by mid-2004 and approval obtained by early 2005. DNAP has a patent pending for compositions and methods relating to OVANOME. Sales of the OVANOME products to labs in 2005 will result in income of $4 million. This product launch will create a new, emerging US market of over $16 million. OVANOME is forecast to reach a peak-year sales record of $12 million in year three and hold steady for several years as the classifier test of choice in this market niche.
Dnap and BREAST CANCER - WOW - we going to the moon
Project ends 2003 Tony could have been right Fda Approval early 2004.
Grant Number: 002/2001 BREAST CANCER - WOW - Testing ends 2003 see below.
PI Name: Arena, J. Fernando - Scientific Advisor to Dnap
Project Title: Development of a BRCA1 and BRCA2 mutation screening assay for women of African descent.
Abstract: DESCRIPTION: (Adapted from investigator's abstract)
The long term objective of this application is to develop and to clinically validate a screening panel for specific BRCA1 and BRCA2 mutation/genetic variants in women of African descent with breast cancer. The development of such panel will allow its incorporation into clinical practice with clear improvement of genetic counseling for this minority population. African-American women under age 50 in the United States have the highest rate of new cases of breast cancer in the nation. In addition, African-American women of all ages have a larger percentage of poorly differentiated breast cancer, that is more likely to occur at an earlier age and to be estrogen and progesterone receptor negative - all factors associated with more aggressive tumorgenicity. Based on this preliminary data and a thorough review of all published English literature, we have identified thirteen mutations and thirteen unclassified variants in BRCA1 and six mutations and ten variants in BRCA2. A screening panel for such BRCA1 and BRCA2 mutations/variants will be designed to develop an efficient assay for eventual use in clinical practice. This assay is based on a combination of multiplex PCR and multiplex SSCP in order to provide a high throughput screening method for the above designated genetic alterations. SSCP variants will be further investigated by DNA sequencing to confirm the exact genetic change. The development of this screening panel will have an important impact on genetic counseling for women of African descent. It may also be helpful in anticipating the design of preventive strategies (mammography, chemoprevention, or prophylactic surgery) and in selecting appropriate therapeutic protocols for this underserved and under investigated patient population.
Institution: UNIVERSITY OF MIAMI
1475 N. W. 12TH AVE.
MIAMI, FL 33136
Fiscal Year: 2001
Department: OB/GYN
Project Start: 01-January, 2002
Project End: 31-December, 2003
FUNDING AGENCY Sylvester Comprehensive Cancer Center
Address: 1475 N.W. 12th Miami Fl, 33136
From the interview. - When asked about ovarian cancer/chemotherapy confirmed that can predict taxol and carboplatin response (based on two genes) and said that they are in the later stages of validating ovanome and "discussing with various types of organizations mechanisms of getting this type of test used and accepted for compensation by insurance companies, etc."
Do you remember last July's stockholder's meeting ? Do you remember this ? From Tony Not Richard
*************************************************************************************************
Ancestry 3.0 would take about a year to develop, but will require between $750K to $1 million to fund the research. DNAP would like to solicit a partner willing to fund it's development in exchange for a share of downstream revenues.
- Ovanome is about a year from market, and DNAP anticipates marketing through a partner. I asked if Statnome was similarly a year out, and the response surprised me. Tony indicated that Statnome would be marketed sooner and the marketing would be handled by DNAP. Obviously, the company is anticipating a much larger market for the Statin classifers which would make it cost effective to run the samples on the UHT.
************************************************************************************************
I really have to share this because i think there's something odd about the fact that there is so little info. out on Statnome that i cant help wonder if Tony is going to pull a BIG Surprise on everyone with News on either Statnome coming out or Ovanome this year. Tony has said Statnome is really top secret and a very big money maker.And then in the EXECUTIVE SUMMARY OF OVANOME we have this -
***************************************************************************************************
The clinical trial for OVANOME will be finished in early 2004. An application for approval to market, if required, will be submitted to the FDA by mid-2004 and approval obtained by early 2005. DNAP has a patent pending for compositions and methods relating to OVANOME. Sales of the OVANOME products to labs in 2005 will result in income of $4 million. This product launch will create a new, emerging US market of over $16 million. OVANOME is forecast to reach a peak-year sales record of $12 million in year three and hold steady for several years as the classifier test of choice in this market niche.
*******************************************************************************************
I guess i would like to believe that Tony is going to pull a Big surprise on us all this year.To much to wish for i guess.Dont mine me i'm just dreaming.
God Bless
Dnap's Statnome info. - This is before Richard gabriel became CEO. After he became CEO you get zip.
From 10Ksb 4-15-2003
Statnome. Statnome is the product we are developing in conjunction with a group of Jacksonville physicians to classify patients as adverse responders or good responders to a class of drugs called statins. Hypercholesterolemic and dyslipidemic patients are at increased risk for heart disease. Currently, these patients are prescribed medications, nicknamed "statins," to reduce this risk.Statins function to decrease cholesterol levels by inhibiting a key enzyme in the cholesterol pathway. According to the National Heart, Lung, and Blood Institute's National Cholesterol Education Program,
high cholesterol is one of the key risk factors for heart disease.
Heart disease is the leading cause of death for both men and women in the United States, and more than 90 million American adults, or about 50 percent of the population, have elevated blood cholesterol levels.
A study published in the New England Journal of Medicine in September 1998 says heart disease deaths have declined steadily over the last 30 years, decreasing by 10.3 percent between 1990 and 1994 alone. This
improvement is largely attributable to better prevention of heart disease through the widespread use of statins.
Notwithstanding the efficacy of this class of drugs, individual patients respond differently to statins. About 2-5% of patients are discontinued from statin treatment due to adverse experiences including hepatocellular toxicity (indicated by elevated serum levels of certain liver enzymes), and more rarely, acute renal failure. In
fact, it is recommended that physicians monitor this toxicity by performing liver function tests prior to, and at 12 weeks following,both the initiation of therapy and any elevation of dose, and periodically thereafter. As a recent Time magazine article points out,statins may potentially serve as a useful preventative tool to reduce
the risk of heart disease in the general, healthy population. A key impediment for the expansion of the statin market in this way is the danger posed by adverse events associated with use of these drugs. For example, the long-term effects of hepatocellular injury are not
clearly understood.
The Statnome product(s) could help reduce the risk associated with the use of statins in the general population. The Company expects its Statin project to result in several "diagnomics" test solutions for
routine patient pre-screening prior to statin prescription. Based on the prevalence of dyslipidemia and hypercholesteremia in the population, such a product could enjoy entry into a market in excess of several billion dollars (drug sales). At present our scientists have completed the screen of the xenobiotic genome for the Statnome project and are validating the performance of the resulting classifier.
***************************************************************************************
10k;
At present our scientists have completed the screen of the xenobiotic genome for the Statnome project and are validating the performance of the resulting classifier.
...and this:
Thus, the Company has scaled back its sample collection efforts and is focusing on validating its Statin prediction product (STATNOME) and building a market for and completing its DNA Witness 2.0 line of forensic products. Pending the acquisition of investment funding or the realization of profits from product sales, DNAPrint intends to resume previous rates of collection for its various developmental stage pharmacogenomics projects.
*************************************************************************************************
From the first Newsletter:
OTHER TESTS - We have finished both the genotyping and the computational screening for Lipitor and Zocor, and we have finished the genotyping but not the computational screening for about 15 other drugs we have good sample sizes for. As we complete these projects, we will disclose the results within a formal, peer-reviewed setting such as a professional meeting or in the scientific literature.
*************************************************************************************************
Sept. 23, 2002--DNAPrint genomics, Inc. (OTCBB:DNAP - News) announced on Friday successful results from its ongoing research into the genetic basis for variable Statin response. The results were presented to an audience of health care professionals at the 7th Annual Disease Management Congress in Chicago, IL.
CEO Dr. Tony Frudakis described Company research that has resulted in the identification of certain gene variants associated with and predictive for Statin response. Statins are a class of drugs used to treat lipid disorders and reduce the risk of cardiovascular disease. Largely due to patient genetics, about 25% of patients fail to respond positively to any given Statin, but those that fail to respond to one often respond to another. The findings are the result of a two-year study that focused on 575 patients and seven different clinical measures of response. Using proprietary screening methods, Company scientists were able to identify an unexpectedly large number of variants linked to response. Those associated with response to standard doses of Artorvastatin (sold under the trade name Lipitor by Pfizer, NYSE:PFE) were generally different from those associated with response to standard doses of Simvistatin (sold under the trade name Zocor by Merck, NYSE:MRK), and those predictive for efficacy (how well the drug does its job) were different from those predictive of adverse events such as early stage hepatocellular toxicity (liver stress) or myalgia (muscle pain). The research condensed mathematical encodings for these variants, which the Company calls "eigengenotypes", into a complex genetics classifier capable of explaining almost all of the observed variability in response. Details on how the "eigengenotypes" were measured and computed, or from what genes they are derived were not presented.
The results were described as the fabric for a new genomics test, called STATNOME(TM), which the Company intends to market to the managed health care industry. By allowing physicians to match patients with the Statin most appropriate for their genetic constitution, STATNOME(TM) could enable a dramatic enhancement the therapeutic benefit of this class of drugs. The Company hopes that STATNOME(TM) will reduce the need for frequent follow up visits to the doctors office, obviate an entire menu of clinical tests for monitoring Statin response and reduce the waste that comes from giving medicines to people who are genetically incapable of responding to them. In so doing, the new test could help managed care providers save thousands of dollars per patient, while at the same time, treat their patients more effectively.
Until the tests are manufactured and distributed, Dr. Frudakis explained that the Company plans to exclusively provide STATNOME(TM) classification services for early clinical adopters and progressive patients. The commencement of this service would be announced at a later date. He also outlined Company plans to begin offering services based on the OVANOME(TM) test, which was introduced by the Company last year as the world's first genomics-based test for flagging patients who are incompatible with paclataxel and carboplatin combination chemotherapy (which is the current FDA approved first-line therapy for ovarian cancer; paclitaxel is sold under the trade name Taxol and carboplatin is sold under the trade name Paraplatin, both are manufactured by Bristol-Myers Squibb, NYSE:BMY). The commencement of STATNOME(TM) and OVANOME(TM) services would make DNAPrint the only laboratory in the world using internally-developed, wholly owned and drug-specific classifiers for the individualization of drug treatment. The tests would be among the very first genomics-based tests ever applied before routine drug use, or for any other clinical practice.
The STATNOME(TM) test could have significant implications for the safety and effectiveness of Artorvastatin and Simvistatin, which combine to serve a $12 billion annual market projected to grow to $20 billion by 2003. Though generally well tolerated, adverse events associated with the use of Statins have recently begun to receive widespread attention. Recently Bayer (NYSE:BAY - News) was forced to pull their Statin "Baycol" from the market due to a fatal response linked to muscle damage and myalgia. Though myalgia is reversible, like hepatocellular toxicity, it is part of a continuum of pathology that leads physicians to switch treatments. By flagging the genetically incompatible before treatment, the Company hopes that STATNOME(TM) will help minimize the negative impact of this widely used class of drugs and change the "trial and error" mentality of today's drug prescription process. In addition, STATNOME(TM) could help expand the market for Statins, many of which are already considered "blockbuster" drugs. For example, Statins are usually given to patients that have a lipid condition that can lead to cardiovascular disease, but there are an estimated 30 million healthy people in the US who are at risk of developing this condition for whom Statins would serve as an effective prophylactic. Mainly due to side effects, and the cost of monitoring these side effects, the cost/impact and risk/reward values for a healthy person at risk of developing a lipid disorder is less desirable than that for the already afflicted. As a result, Statins are still not used in the healthy population. By accurately flagging those who would develop an adverse reaction to them before the drug is given, STATNOME(TM) could someday help Statins overcome this barrier for more widespread use.
*************************************************************************************************Some of the Statinome drugs DNAP is reviewing...01-01-02
Baycol........>now banned by the FDA for high risks involved.
Lescol
Lipitor
Lopid
Mevacor
Niacin
Niaspan
Pravachol
Zocor
http://www.dnaprint.com/bioform.pdf
*************************************************************************************************
From the shareholders meeting March, 2003 -Reported by worktoplay - post# 232636
Ovanome is about a year from market, and DNAP anticipates marketing through a partner. I asked if Statnome was similarly a year out, and the response surprised me. Tony indicated that Statnome would be marketed sooner and the marketing would be handled by DNAP. Obviously, the company is anticipating a much larger market for the Statin classifers which would make it cost effective to run the samples on the UHT.
*************************************************************************************************
You better read this - Biometrics: A Look at Facial Recognition >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
http://www.rand.org/publications/DB/DB396/DB396.pdf
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
DNAPrint Joins National Institutes of Justice Funded Project
Monday August 25,2003 -- 11:25 am ET
SARASOTA, Fla., Aug. 25 /PRNewswire-FirstCall/ -- DNAPrint Genomics, Inc. (OTC Bulletin Board: DNAP - News; DNAPrint or the "Company") announced today that it will serve as a subcontractor for a new National Institutes of Justice (the "NIJ") research grant.
DNAPrint will apply its expertise in the measurement of population structure and genome screening to assist the NIJ and the grantee map genetic markers of a certain forensics value, considered by the Company to be complementary to its DNAWitness efforts. The project is broken into two- phases, the first of which has already been approved. The Company would be paid approximately $50,000 to produce approximately 80,000 genotypes. Other details are not disclosed.
About DNAPrint genomics, Inc.
DNAPrint(TM) genomics, Inc., ("DNAPrint(TM)" or the "Company"), is a genomics science company focused on the sale of proprietary genetic testing products and services. The Company's core technologies for efficiently targeting single nucleotide polymorphisms ("SNPs") enable it to provide predictive genetic tests at a significant cost advantage over its competitors.
The Company has identified and patented the maps of certain SNPs with wide commercial applications. These commercially valuable SNP maps are called Ancestry Informative Markers ("AIMS"). The Company's patented AIMs are integral to the Company's strategy of offering DNA tests that provide valuable predictive results, including a person's physical characteristics, Biogeographical Ancestry ("BGA"), and predisposition to respond to certain pharmaceutical drugs. The Company's tests target four distinct markets -- forensics, consumer, and pharmacogenomics (predicting drug response) and outsourced screening services. The Company is traded on the Nasdaq OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit www.dnaprint.com.
All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Moffitt gets millions for national genomics project
Stacey Snow
Staff Writer Sept 13,2002
Doctors may soon be able to tailor cancer treatments to a patient's genetic makeup, and pharmaceutical companies could manufacture more effective drugs.
H. Lee Moffitt Cancer Center & Research Institute plans to work on turning those possibilities into realities, with the help of a $3.2-million federal grant.
The U.S. Department of Defense awarded Moffitt the grant to establish the National Functional Genomics Project.
Moffitt researchers intend to prove that identifying the unique makeup of each cancer cell will lead to treatments that kill it.
The project's research could result in better drugs to treat a variety of diseases, including cancer, heart disease or Alzheimer's disease, said Jack Pledger, Moffitt's deputy director, head of basic research and professor in Moffitt's Interdisciplinary Oncology Program with the University of South Florida.
The genomics project will allow government beneficiaries more rapid access to new technologies and advances in health care.
The first goal is to track genetic changes involved in cancer, creating a better understanding of hereditary and environmental influences that contribute to the disease. Researchers will also evaluate potential for commercial development of new technologies based on Moffitt's translational research — the application of laboratory results into patient care.
The implications for the Tampa cancer center are significant, Pledger said.
In the project's first year Moffitt will need to add between five and 10 new employees, including several scientists. However, as the program progresses along its five-year plan, as many as 100 new employees could be needed, Pledger said. The federal grant covers the first year of the program, but Pledger hopes more funding will be forthcoming as the project gains momentum.
The designation as the lead institution on the project also means more visibility for a cancer center working to enhance its national reputation. Moffitt, designated a Comprehensive Cancer Center by the National Cancer Institute, also was listed in U.S. News & World Report as one of the top 10 cancer hospitals in the country.
"This is one of the things that helps you move up the ranks," Pledger said.
"Functional genomics is the hottest topic in cancer research today," stated Dr. William Dalton, Moffitt's chief executive officer and center director, in a release. "It could completely change the practice of medicine within five years."
The project will be a partnership between academia, government and industry. Moffitt researchers hope that will serve as a paradigm for future collaborations, Pledger said.
Getting pharmaceutical companies, medical manufacturers and other businesses involved will allow them to be at the forefront of new developments and to create products based on the latest in medical research, he said.
H. Lee Moffitt Cancer Center and Research Institute
The H. Lee Moffitt Cancer Center and Research Institute is a nationally recognized hospital and research center for cancer prevention and treatment. It is one of only 38 National Cancer Institute-designated Comprehensive Cancer Centers in the U.S. At its location on the USF campus, more than 700 Moffitt scientists and clinicians oversee some 200 grant-supported research projects. A new Vincent A. Stabile Research Building opened last year, adding 200,000 square feet more laboratory space. Funded research projects totaled $53 million in 2003.
Moffitt is known for its landmark research discoveries in the area of functional genomics, molecular targeting, anti-cancer vaccines and genetic testing. A $3.2 million U.S. Department of Defense grant is helping establish the National Functional Genomics Center. Moffitt scientists are using functional genomics to profile cancer cells and examine how genes instruct cells to become normal or abnormal.
Biometrics Council on Terrorism meeting - attended by Tony Frudakis:
http://www.findbiometrics.com/Pages/news_releases/news451.html
Tom Colatosti, Chairman of BIO-key International and CEO of American Security Ventures Appointed to Advisory Board of Biometrics Council - May 22, 2003
Two recent college graduates, David J. Harris and Wm. Matthew Jaunich, have founded Biometrics Council, a non-profit organization dedicated to fostering public awareness of the potential of biometrics to substantially reduce the risk of terrorism to the United States. Mr. Harris graduated from Yale College in 2000, where he worked for former President Bush's brother, Jonathan, at his investment firm, J. Bush and Company, Inc. In addition, Mr. Harris co-authored the first study of women in cardiac trials funded by the National Institutes of Health in the New England Journal of Medicine. Mr. Jaunich, an honors graduate of the University of Southern California, is President of the Lucror Group, L.L.C., a private equity vehicle and consults for Fremont Partners, L.P., a merchant bank in San Francisco. Mr. Jaunich has also worked for Creative Artists Agency in Hollywood.
Within a few weeks, Mr. Harris and Mr. Jaunich have recruited luminaries of the intelligence community, academe and industry to the Board of Directors:
Arnaud de Borchgrave, Editor at Large, Washington Times; UPI, and Director, Transnational Threats, Center for Strategic and International Studies, Member, Secretary Ridge's Advisory Committee for Homeland Security
Margaret L. Johnson, Senior Lecturer, Department of Computer Science, Department of Symbolic Systems, Stanford University
Catherine Lotrionte, Adjunct Professor of Security Studies, Georgetown University. Professor Lotrionte's particular areas of expertise are national security law, international law and international security.
Carlos L. Signoret, Managing Director, Hispania Capital Partners.
In addition to the Board of Directors, Biometrics Council has an Advisory Committee of leaders from the industry, who offer insight but have no governance power.
The advisors are:
Alexander and Michael Bronstein, Members of the 3DFACE Research Group, Technion -- Israel Institute of Technology, twenty-two year old identical twins who developed a facial recognition algorithm that distinguishes between them, which was featured on CNN.
Thomas J. Colatosti, Chairman of the Board, BIO-key International (OTC Bulletin Board: BKYI) and Founder and Chief Executive Officer of American Security Ventures.
R. Terren "Terry" Dunlap, Chief Executive Officer of Ultra-Scan Corporation
Tony Frudakis, Founder, Chief Executive Officer and President of DNAPrint Genomics
Barry Hodge, President of AcSys Biometrics Corporation
Oliver "Buck" Revell, Chairman of the Board of Imagis Technologies, Inc. and retired Associate Deputy Director of the Federal Bureau of Investigation (FBI).
Biometrics Council is market-neutral and all directors have pledged not to own biometrics securities or accept profit incentives from the industry. This underscores their commitment to the proposition that biometrics in its various modalities, including facial-recognition, fingerprint, DNA, retinal and iris, palm and vein, could in a variety of applications enhance the safety of the American people.
Mr. Harris explained the Council's motivation: "Overwhelming evidence demonstrates that the use of weapons of mass destruction against the United States is imminent.
Warren Buffett, for instance, has declared that a nuclear attack on America is 'virtually a certainty.' If we are to preserve the American way of life, we must have a revolution in infrastructure. We believe a vital piece of this is biometrics."
Arnaud de Borchgrave stated, "The next generation will see electronics worn, ingested or implanted. Biometrics is an integral part of our national security as disruptive technologies keep America at the cutting edge of revolutionary change."
"After September 11, there was a surge in interest concerning identity technology, but this crest has fallen, and we are in an almost tranquil abeyance, a denial of the immediacy of the threat," Harris added.
Mr. Harris stresses this is not a partisan issue. "Secretary Rumsfeld has admonished that a weapons of mass destruction attack on America is not a matter of 'if', but 'when.'
Congressman Edward Markey, a Massachusetts Democrat, has been sounding the clarion call that we cannot continue status quo operation of nuclear power plants, given that they are capable of being weaponized. We want to seek out more people who do not view the threat of weapons of mass destruction through rose-colored glasses."
The Council has had discussions with various officials in the government, both active and retired, and is heartened by the interest in its initiatives. Lt. General Claudia Kennedy, former Deputy Chief of Staff of the Army for Intelligence, the first and only woman to achieve that rank in the United States Army, attended the Council's first meeting this winter.
SOURCE: Biometrics Council
WOW it cant get better than this.What Dnap and Stanford again !!!!!
http://64.233.167.104/search?q=cache:SMDsS3kr608J:www.csis.org/tnt/031104.pdf+Dr.+Tony+Frudakis&....
Biometrics and Counter-Terrorism
A Roundtable hosted by CSIS Transnational Threats Initiative
November 4, 2003
Biometrics and counter-terrorism was the key topic at a CSIS Biometrics Roundtable held on November 4, 2003. The roundtable hosted by the Transnational Threats Initiative, brought together speakers from corporate, academic, and the government communities to discuss the impact of biometrics on both terrorism and civil liberties.
Biometrics are an important security instrument as America and the world adapt to asymmetric warfare and the widespread use of fraudulent identification documents. The roundtable addressed civil liberty concerns that arise with the widespread use of biometrics technology, a sensitive political issue on which America has been largely silent. While there has been much discussion on biometric applications, very rarely have there been detailed efforts to address the constitutional implications of the technology.
In his keynote remarks, Jeff Jonas, founder and chief scientist of Systems Research and Development discussed the issue of identity in the age of asymmetric threat.
The first panel addressed future biometrics applications with highlights on homeland defense, intelligence surveillance, and forensic technology. Panel members included John Woodward, Director of the Biometrics Management Office at the Department of Defense, Dr. Tony Frudakis, Chief Scientific Officer and Founder of DNAPrint Genomics, Barry Hodge, President of AcSys Biometrics Corporation and Dr. Andrew Kirby, Senior Physical Scientists, Intelligence Technology and Innovation Center at the CIA.
The second panel addressed biometrics and the implications of civil liberties. Panel members included Dr. Margaret Johnson, Senior Lecturer from the Department of Computer Science at Stanford University, David Harris, President and Founder of Biometrics Council, Dr. Catherine Lotrionte, Adjunct Professor at Georgetown University and Dr. Anthony Arend, Professor of Government at Georgetown University.
The host of that event was the Transnational Threats Initiative. More information on that effort can be found here:
http://www.csis.org/tnt/
While organized crime is not a new phenomenon today, some governments find their authority besieged at home and their foreign policy interests imperiled abroad. Drug trafficking, links between drug traffickers and terrorists, smuggling of illegal aliens, massive financial and bank fraud, arms smuggling, potential involvement in the theft and sale of nuclear material, political intimidation, and corruption all constitute a poisonous brew—a mixture potentially as deadly as what we faced during the cold war.
R. James Woolsey
Former Director of Central Intelligence and
Transnational Threats Initiative Steering Committee Member
The Transnational Threats Initiative Steering Committee and Members List contains some interesting names. You'll recognize several of them as members and advisors to the Biological Threats Council, of which Tony Frudakis is an Advisory Member:
Steering Committee
Leadership
The project is chaired by William Webster, former Director of the CIA and FBI. CSIS Senior Adviser Arnaud de Borchgrave serves as Project Director, CSIS Senior Analyst Thomas Sanderson as the Deputy Director with CSIS Senior Adviser Robert Kupperman and CSIS Director of Studies Erik Peterson as Co-Directors.
Members
Hon. Duane Andrews: Former Assistant Secretary of Defense
Ms. Zoe Baird: President, John and Mary Markle Foundation
Hon. Robert C. Bonner: Former Administrator, DEA, currently Commissioner, U.S. Customs Service (on leave)
Hon. William Cohen: Former United States Senator, former Secretary of Defense, and currently Chairman and CEO, Cohen Group
Mr. Charles Connolly: Former CSO, Merrill Lynch
Hon. John Deutch: Former Director, CIA and currently Institute Professor, Department of Chemistry, MIT
Mr. Richard Fore: Chairman, Fore Property Company
Hon. Robert Gates: Former Director CIA and currently President, Texas A&M
Hon. Carol Hallett: Former Commissioner, U.S. Customs Service and current Vice Chairman, Aviation Safety Alliance Carmen Group and Senior Advisor, Air Transportation Association
Admiral James R. Hogg: U.S. Navy (Ret.) and currently Director, Strategic Studies Group, Naval War College
Hon. Fred Ikle: Former Under Secretary of Defense and currently Distinguished Scholar, CSIS
Dr. David Kay: Corporate Vice President-Homeland Security, SAIC
Hon. Stuart Knight: Former Director, Secret Service
Hon. Jon Kyl: United States Senator (R - AZ)
Dr. Walter Laquer: Distinguished Scholar, CSIS
Hon. Patrick Leahy: United States Senator (D - VT)
Mr. Ronald A. Marks: Director, Federal Business Development, Sytegra Federal
Hon. William McCollum: Former U.S. Representative (R - FL) and currently Partner, Baker & Hostetler, LLP
General Edward C. Meyer: Former Chief of Staff, U.S. Army and currently Chairman, Mitretek Systems Inc.
Hon. Sam Nunn: Former United States Senator
Mr. Oliver ("Buck") Revell: Former Associate Deputy Director, Federal Bureau of Investigation and currently President, Revell Group International, Inc.
Hon. Donald Rumsfeld: U.S. Secretary of Defense (on leave)
Hon. James R. Schlesinger: Former Secretary of Defense, former Secretary of Energy, former CIA Director, and currently Senior Advisor, Lehman Brothers, Inc.
Hon. William Sessions: Former Director, FBI and currently Partner, Holland & Knight, LLP
Admiral William D. Smith: U.S. Navy (Ret.) and Senior Fellow, Center for Naval Analyses
Lt. General Edward Soyster: Former Director, DIA and currently Vice President-International Operations, Military Professional Resources, Inc.
Hon. Richard Thornburgh: Former Attorney-General, former Governor of Pennsylvania and currently Counsel, Kirkpatrick & Lockhart LLP
Hon. William Webster: Senior Partner, Milbank, Tweed, Hadley & McCloy
Hon. Curt Weldon: U.S. Representative (R - PA)